Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2011 pubmed 207 citations

Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.

Dean. Scott N SN; Bishop. Barney M BM; van Hoek. Monique L ML

Key Findings

  • LL‑37 kills S. aureus and blocks biofilm formation at low µg/ml levels
  • The all‑D version (D‑LL‑37) keeps activity and is resistant to proteases
  • A short synthetic cobra‑derived peptide (NA‑CATH:ATRA1‑ATRA1) is more potent against biofilms in salty environments and shows low toxicity

Practical Outcomes

  • The study suggests that peptide‑based topical treatments could eventually improve healing of chronic, infected wounds by targeting biofilms. For now, biohackers can view these peptides as promising templates, but they’re not yet available as safe, affordable DIY products. Future work may focus on low‑dose, stable formulations that can be applied directly to wounds.

Summary

Researchers tested natural and synthetic versions of the antimicrobial peptide LL‑37 and related snake‑derived peptides against Staph aureus, a common wound‑infecting bug that forms tough biofilms. They found that LL‑37 and a mirror‑image version (D‑LL‑37) can kill the bacteria and stop biofilm formation at very low concentrations, and a specially designed short peptide from the cobra (NA‑CATH:ATRA1‑ATRA1) works even better in salty conditions with little toxicity to human cells. These results point to peptide‑based creams or gels as a future way to treat chronic infected wounds, though they’re still early‑stage lab findings.

Abstract

Chronic, infected wounds typically contain multiple genera of bacteria, including Staphylococcus aureus, many of which are strong biofilm formers. Bacterial biofilms are thought to be a direct impediment to wound healing. New therapies that focus on a biofilm approach may improve the recovery and healing rate for infected wounds. In this study, cathelicidins and related short, synthetic peptides were tested for their anti-microbial effectiveness as well as their ability to inhibit the ability of S. aureus to form biofilms. The helical human cathelicidin LL-37 was tested against S. aureus, and was found to exhibit effective anti-microbial, anti-attachment as well as anti-biofilm activity at concentrations in the low μg/ml range. The effect of peptide chirality and associated protease-resistance was explored through the use of an all-D amino acid peptide, D-LL-37, and in turn compared to scrambled LL-37. Helical cathelicidins have been identified in other animals such as the Chinese cobra, Naja atra (NA-CATH). We previously identified an 11-residue imperfectly repeated pattern (ATRA motif) within the sequence of NA-CATH. A series of short peptides (ATRA-1, -2, -1A), as well as a synthetic peptide, NA-CATH:ATRA1-ATRA1, were designed to explore the significance of the conserved residues within the ATRA motif for anti-microbial activity. The CD spectrum of NA-CATH and NA-CATH:ATRA1-ATRA1 revealed the structural properties of these peptides and suggested that helicity may factor into their anti-microbial and anti-biofilm activities. The NA-CATH:ATRA1-ATRA1 peptide inhibits the production of biofilm by S. aureus in the presence of salt, exhibiting anti-biofilm activity at lower peptide concentrations than NA-CATH, LL-37 and D-LL-37; and demonstrates low cytoxicity against host cells but does not affect bacterial attachment. The peptides utilized in this anti-biofilm approach may provide templates for a new group of anti-microbials and potential future topical therapeutics for treating chronic wound infections.

Study Information

Provider

pubmed

Year

2011

Date

2011-05-23T00:00:00.000Z

DOI

10.1186/1471-2180-11-114

Citations

207

References

51